Arizona
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Arizona: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Arizona generally follows federal patent rules, particularly regarding the patentability of naturally occurring products. The state courts emphasize the balance between protecting innovation and ensuring public access to fundamental knowledge, aligning with the principles established in Myriad.
In Arizona, as guided by federal precedents, DNA sequences that are isolated and not altered in a way that changes their natural function may not be patentable, maintaining the stance that laws of nature, natural phenomena, and abstract ideas are not eligible for patent protection.
Arizona courts declined to grant patent protection for a compound that was found to naturally occur, echoing the sentiment in Myriad.
The court reinforced that innovations must present a new and useful process or machine rather than discovery of naturally occurring substances.
Patents on naturally occurring nucleotide sequences were deemed invalid as they did not demonstrate sufficient transformation to be patentable under state law.
Arizona's application of principles from Myriad aligns closely with federal guidelines, particularly the prohibition against patenting naturally occurring products. While federal courts have emphasized the need for transformative alterations, Arizona's courts echo this rationale in several local cases.
Understanding the implications of Myriad in Arizona is relevant for the Arizona bar exam, particularly in sections covering patent eligibility under both federal and state law.